Profile data is unavailable for this security.
About the company
OS Therapies Incorporated is a clinical-stage biopharmaceutical company. The Company is focused on the identification, development and commercialization of treatments for Osteosarcoma (OS) and other solid tumors. It built a pipeline of product candidates targeting multiple indications for solid cancers. Its pipeline includes two drug technologies: OST-HER2 and OST-tADC. OST-HER2 is an off-the-shelf immunotherapy, which is a type of cancer treatment that helps one’s immune system fight cancer, comprised of a genetically weakened and modified strain of Listeria monocytogenes, a species of bacteria that causes the infection listeriosis, that expresses HER2 peptides. OST-tADC is a tunable ADC with a plug-and-play platform that features tunable pH sensitive silicone linkers (SiLinkers). The payloads can include antibodies, chemotherapeutics, cytotoxins and potentially mRNA treatments directly into and in the vicinity of solid tumors.
- Revenue in USD (TTM)0.00
- Net income in USD-7.42m
- Incorporated2018
- Employees4.00
- LocationOS Therapies Inc15825 Shady Grove Road, Suite 135ROCKVILLE 20850United StatesUSA
- Phone+1 (410) 297-7793
- Fax+1 (302) 655-5049
- Websitehttps://ostherapies.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Carisma Therapeutics Inc | 20.27m | -63.80m | 35.40m | 107.00 | -- | -- | -- | 1.75 | -1.56 | -1.56 | 0.4927 | -0.2665 | 0.2723 | -- | -- | 189,420.60 | -85.73 | -30.87 | -101.81 | -34.47 | -- | -- | -314.78 | -255.66 | -- | -- | -- | -- | -62.70 | -- | -336.93 | -- | 255.27 | -- |
| Elevation Oncology Inc | 0.00 | -41.95m | 35.78m | 29.00 | -- | 0.5159 | -- | -- | -0.807 | -0.807 | 0.00 | 1.17 | 0.00 | -- | -- | 0.00 | -40.67 | -- | -43.53 | -- | -- | -- | -- | -- | -- | -375.06 | 0.309 | -- | -- | -- | 51.93 | -- | -- | -- |
| NextCure Inc | 0.00 | -58.52m | 36.13m | 82.00 | -- | 0.4774 | -- | -- | -2.09 | -2.09 | 0.00 | 2.70 | 0.00 | -- | -- | 0.00 | -50.82 | -22.59 | -54.42 | -23.54 | -- | -- | -- | -964.96 | -- | -- | 0.00 | -- | -- | -- | 16.07 | -- | -23.17 | -- |
| CERo Therapeutics Holdings Inc | 0.00 | -2.54m | 36.58m | 8.00 | -- | -- | -- | -- | -0.3796 | -0.3796 | 0.00 | -0.9226 | 0.00 | -- | -- | 0.00 | -9.96 | -- | -33.80 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -279.82 | -- | -- | -- |
| Rapt Therapeutics Inc | 0.00 | -107.49m | 36.65m | 70.00 | -- | 0.3837 | -- | -- | -2.78 | -2.78 | 0.00 | 2.74 | 0.00 | -- | -- | 0.00 | -69.76 | -46.30 | -77.90 | -49.97 | -- | -- | -- | -3,522.72 | -- | -- | 0.00 | -- | -100.00 | -- | -39.31 | -- | -20.31 | -- |
| AN2 Therapeutics Inc | 0.00 | -60.70m | 36.75m | 41.00 | -- | 0.419 | -- | -- | -2.04 | -2.04 | 0.00 | 2.94 | 0.00 | -- | -- | 0.00 | -48.27 | -- | -53.56 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -51.33 | -- | -- | -- |
| Intensity Therapeutics Inc | 0.00 | -16.26m | 37.18m | 5.00 | -- | 13.47 | -- | -- | -1.18 | -1.18 | 0.00 | 0.2005 | 0.00 | -- | -- | 0.00 | -147.61 | -- | -171.25 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -56.45 | -- | -- | -- |
| OS Therapies Inc | 0.00 | -7.42m | 37.23m | 4.00 | -- | -- | -- | -- | -0.3566 | -0.3566 | 0.00 | -0.0334 | 0.00 | -- | -- | 0.00 | -559.23 | -- | -- | -- | -- | -- | -- | -- | -- | -2.13 | -- | -- | -- | -- | -24.09 | -- | -- | -- |
| Lumos Pharma Inc | 2.21m | -34.92m | 37.45m | 30.00 | -- | 7.62 | -- | 16.98 | -4.29 | -4.29 | 0.2705 | 0.5682 | 0.0676 | -- | 12.75 | 66,818.18 | -107.08 | -29.78 | -132.78 | -32.32 | -- | -- | -1,583.49 | -2,937.61 | -- | -- | 0.00 | -- | 34.67 | -30.31 | -9.57 | -- | -- | -- |
| Calidi Biotherapeutics Inc | 0.00 | -27.95m | 37.66m | 41.00 | -- | -- | -- | -- | -5.61 | -5.61 | 0.00 | -1.10 | 0.00 | -- | -- | 0.00 | -208.29 | -- | -2,279.15 | -- | -- | -- | -- | -- | -- | -28.13 | -- | -- | -100.00 | -- | -14.90 | -- | -- | -- |
| FibroGen Inc | 180.01m | -121.79m | 38.88m | 486.00 | -- | -- | -- | 0.216 | -1.23 | -1.23 | 1.81 | -2.42 | 0.4967 | 1.29 | 7.49 | 370,399.20 | -34.51 | -30.62 | -103.81 | -42.31 | 76.87 | 93.52 | -69.48 | -119.08 | 1.16 | -7.70 | -- | -- | 4.99 | -7.05 | 3.21 | -- | -20.67 | -- |
| Anebulo Pharmaceuticals Inc | 0.00 | -7.92m | 38.90m | 2.00 | -- | 20.49 | -- | -- | -0.306 | -0.306 | 0.00 | 0.0732 | 0.00 | -- | -- | 0.00 | -137.58 | -- | -154.87 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 30.09 | -- | -- | -- |
| LAVA Therapeutics NV | 7.40m | -24.18m | 38.91m | 37.00 | -- | 0.9077 | -- | 5.26 | -0.8976 | -0.8976 | 0.2741 | 1.63 | 0.0689 | -- | 3.23 | 199,946.00 | -22.51 | -- | -27.11 | -- | 97.78 | -- | -326.89 | -- | -- | -- | 0.1257 | -- | -65.09 | -- | -31.55 | -- | -- | -- |
| Iterum Therapeutics PLC | 0.00 | -30.55m | 40.19m | 14.00 | -- | -- | -- | -- | -2.00 | -2.00 | 0.00 | -0.5068 | 0.00 | -- | -- | 0.00 | -109.80 | -118.12 | -297.32 | -199.23 | -- | -- | -- | -890,554.10 | -- | -7.38 | 2.05 | -- | -- | -- | 13.64 | -- | -32.09 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Millennium Management LLCas of 30 Sep 2024 | 60.44k | 0.29% |
| CM Management LLCas of 30 Sep 2024 | 50.00k | 0.24% |
| Delta Investment Management LLCas of 30 Sep 2024 | 18.08k | 0.09% |
| HRT Financial LP (US)as of 30 Sep 2024 | 17.58k | 0.08% |
| UBS Securities LLCas of 30 Sep 2024 | 3.81k | 0.02% |
| Armstrong Advisory Group, Inc.as of 30 Sep 2024 | 100.00 | 0.00% |
